NCT01066546View on ClinicalTrials.gov

An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease

PHASE3TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Alzheimer's Disease
Interventions
DRUG

Dimebon tablet for oral administration

10 mg TID for Week 1, followed by 20 mg TID for remainder of study

Trial Locations (5)

33445

Pfizer Investigational Site, Delray Beach

90720

Pfizer Investigational Site, Los Alamitos

91316

Pfizer Investigational Site, Encino

92626

Pfizer Investigational Site, Costa Mesa

92660-2452

Pfizer Investigational Site, Newport Beach

Sponsors

Lead Sponsor

Pfizer

Collaborators (1)

Medivation, Inc.
All Listed Sponsors
collaborator

Medivation, Inc.

INDUSTRY

lead

Pfizer

INDUSTRY